HomeCompareLABP vs EQR

LABP vs EQR: Dividend Comparison 2026

LABP yields 8.72% · EQR yields 4.73%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EQR wins by $4.8K in total portfolio value· pulled ahead in Year 8
10 years
LABP
LABP
● Live price
8.72%
Share price
$22.93
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$35.6K
Annual income
$1,512.64
Full LABP calculator →
EQR
EQR
● Live price
4.73%
Share price
$58.58
Annual div
$2.77
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.5K
Annual income
$3,819.61
Full EQR calculator →

Portfolio growth — LABP vs EQR

📍 EQR pulled ahead of the other in Year 8

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLABPEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LABP + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
LABP pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LABP
Annual income on $10K today (after 15% tax)
$741.39/yr
After 10yr DRIP, annual income (after tax)
$1,285.74/yr
EQR
Annual income on $10K today (after 15% tax)
$401.93/yr
After 10yr DRIP, annual income (after tax)
$3,246.67/yr
At 15% tax rate, EQR beats the other by $1,960.92/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LABP + EQR for your $10,000?

LABP: 50%EQR: 50%
100% EQR50/50100% LABP
Portfolio after 10yr
$38.0K
Annual income
$2,666.12/yr
Blended yield
7.01%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

LABP
Analyst Ratings
2
Buy
4
Hold
1
Sell
Consensus: Hold
Altman Z
-3.1
Piotroski
2/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+20.1% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LABP buys
0
EQR buys
0
No recent congressional trades found for LABP or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLABPEQR
Forward yield8.72%4.73%
Annual dividend / share$2.00$2.77
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$35.6K$40.5K
Annual income after 10y$1,512.64$3,819.61
Total dividends collected$11.9K$16.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusHoldHold

Year-by-year: LABP vs EQR ($10,000, DRIP)

YearLABP PortfolioLABP Income/yrEQR PortfolioEQR Income/yrGap
1$11,572$872.22$11,248$547.57+$324.00LABP
2$13,326$943.32$12,701$666.53+$625.00LABP
3$15,274$1,015.18$14,405$814.59+$869.00LABP
4$17,430$1,087.46$16,413$999.84+$1.0KLABP
5$19,810$1,159.83$18,795$1,232.92+$1.0KLABP
6$22,429$1,231.95$21,639$1,527.95+$790.00LABP
7$25,302$1,303.55$25,057$1,903.80+$245.00LABP
8← crossover$28,448$1,374.36$29,197$2,385.87$749.00EQR
9$31,883$1,444.13$34,250$3,008.70$2.4KEQR
10$35,628$1,512.64$40,467$3,819.61$4.8KEQR

LABP vs EQR: Complete Analysis 2026

LABPStock

Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. The company's lead product candidate in development include omilancor, a gut-restricted oral therapeutic candidate that targets lanthionine synthetase C-like protein 2 (LANCL2) for the treatment of ulcerative colitis (UC), Crohn's disease (CD), and eosinophilic esophagitis; NX-13, a gut-restricted oral therapeutic that targets NOD-like receptor X1 (NOD-like), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines for UC and CD; and LABP-104, an orally-active and systemically bioavailable small molecule therapeutic candidate that targets LANCL2 agonist for the treatment of systemic lupus erythematosus and rheumatoid arthritis (RA). Its preclinical candidates in development include LABP-66 is an oral and small molecule NOD-like pathway agonist for the treatment of multiple sclerosis and Alzheimer's disease; LABP-69, an oral PLXDC2 agonist for the treatment of diabetic nephropathy and RA; LABP-73, an oral and small molecule NLRX1 pathway agonist in development for the treatment of asthma and chronic obstructive pulmonary disease; and LABP-111, an oral and small molecule LANCL2 pathway agonist for the treatment of nonalcoholic steatohepatitis and type 1 diabetes. The company was incorporated in 2017 and is headquartered in Blacksburg, Virginia.

Full LABP Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this LABP vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LABP vs SCHDLABP vs JEPILABP vs OLABP vs KOLABP vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.